Abstract:Abstract Background: The oncogenic transcription factor HOXB13, which is highly expressed in castration-resistant prostate cancer (CRPC), has been shown to promote CRPC growth and metastasis. However, HOXB13 is considered untargetable by traditional small-molecule-based drug design. Gene therapy is critical alternative strategy with potential to directly target such traditionally undruggable genes. Methods: Selective cell in organ targeting (SCORT) nanoparticles for precise delivery of nanoparticles to metastatic cancer cells in an organ were constructed and characterized by the NanoAssemblr Spark, Zetasizer Nano ZS, and transmission electron microscopy (TEM); Cas13d mRNA with pseudouridine modification was synthesized using in vitro transcription; Hemi-spleen injection of CRPC cells was performed to build CRPC liver metastatic models; RNA-seq was employed to evaluate off-target effects of Cas13d targeting. Results: By incorporating a prostate cancer-specific E3 aptamer to functionalized lipid-like nanoparticles (FTT5 LNP-E3), we have successfully constructed SCORT nanoparticles that enable preferential delivery of mRNAs to metastatic CRPC cells in the liver, as opposed to various normal cells in the surrounding liver tissue. We demonstrated that Cas13d-pre-gHOXB13 mediates highly effective and specific HOXB13 mRNA knockdown in CRPC cells. Significantly, systemic treatment of SCORT nanoparticles carrying Cas13d-pre-gHOXB13 mRNA decreased HOXB13 expression in the metastatic tumors, inhibited metastasis, and prolonged survival of mice bearing androgen receptor (AR)-positive (AR+) or negative (AR-) tumors. Notably, long term (6 and a half weeks) administration of SCORT nanoparticle-Cas13d-pre-gHOXB13 did not significant alter body weight, hepatic and renal function, chemokines and cytokines, and other factors, effectively highlighting its safety. Conclusions: This study is the first to demonstrate that undruggable oncogenic transcription factors can be targeted using nanoparticle-delivered gene therapy based on CRISPR/Cas13 RNA-targeting. The SCORT-CRISPR/Cas13d system is a highly flexible technology that would impact the larger field of translational science by allowing the design of Cas13d-based, cancer cell-specific delivered nanoparticles targeting other previously-undruggable oncogenic transcription factors in metastatic prostate cancer and other solid tumors. Citation Format: Zhifen Cui, Furong Huang, Kun Fang, Jingyue Yan, Yufan Zhou, Jeffrey Everitt, Yue Zhao, William Hankey, Zhong Chen, Hongyan Wang, Victor X. Jin, Yizhou Dong, Qianben Wang. Targeting undruggable transcription factor HOXB13 in metastatic prostate cancer by CRISPR/Cas13d-based nanoparticle therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 495.

[Knocking-out of HIF1α Gene by CRISPR/cas9 Inhibits Proliferation and Invasiveness of Prostate Cancer DU145 Cells].

Genome-Wide CRISPR-Cas9 Screening and Identification of Potential Genes Promoting Prostate Cancer Growth and Metastasis

Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer.

RNA Interference Targeting Mutant P53 Inhibits Growth and Induces Apoptosis in DU145 Human Prostate Cancer Cells

Silencing of HOXB9 suppresses cellular proliferation, angiogenesis, migration and invasion of prostate cancer cells

HOXA1 Enhances the Cell Proliferation, Invasion and Metastasis of Prostate Cancer Cells

Knockdown of ET-1 Gene Can Inhibit the Proliferation, Invasion of Human Prostate Cancer Cell

CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds

Targeted Delivery of CRISPR/Cas9 to Prostate Cancer by Modified Grna Using a Flexible Aptamer-Cationic Liposome

Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity

Abstract 495: Targeting undruggable transcription factor HOXB13 in metastatic prostate cancer by CRISPR/Cas13d-based nanoparticle therapy

Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer

Knockdown of KIF15 Suppresses Proliferation of Prostate Cancer Cells and Induces Apoptosis Through PI3K/Akt Signaling Pathway

lncRNA HOX Transcription Antisense RNA Knockdown Has Anti-Tumor Effects to Prostatic Cancer In Vitro Study

HuR promotes castration-resistant prostate cancer progression by altering ERK5 activation via posttranscriptional regulation of BCAT1

Selective Targeting of an Oncogenic KRAS Mutant Allele by CRISPR/Cas9 Induces Efficient Tumor Regression

Effect of Hypoxia-Inducible Factor-1Α on Proliferation and Invasion of Prostate Cancer PC-3 Cell in Hypoxic Situation

Targeting Upar by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance

Various Effects of Hepatoma-Derived Growth Factor on Cell Growth, Migration and Invasion of Breast Cancer and Prostate Cancer Cells.

Selective Targeting of the Oncogenic KRAS G12S Mutant Allele by CRISPR/Cas9 Induces Efficient Tumor Regression

Silencing of HIF-1α Suppresses Tumorigenicity of Renal Cell Carcinoma Through Induction of Apoptosis